TNFSF4, TNF superfamily member 4, 7292

N. diseases: 129; N. variants: 32
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE So, we reviewed the OX40 and its ligand (OX40L) function in cancer, clinical trials with OX40/OX40L and the correlation between OX40/OX40L and other immune checkpoints to add more ideas to tumor feasible treatment. 31564917 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 AlteredExpression group BEFREE IL-23/IL-36γ/OX40L triplet mRNA mixture triggered substantial immune cell recruitment into tumors, enabling effective tumor destruction irrespective of previous tumoral immune infiltrates. 30700577 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE In this study, the relationship between OX40/OX40L expressed on tumor infiltrating lymphocytes (TILs), PD-1/PD-L1 and other immunological factors, as well as its role serving as the potential prognostic biomarker, were analyzed in NSCLC. 31555511 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 AlteredExpression group BEFREE TNFSF4 mRNA is expressed in melanoma cell lines and melanoma samples, including those with low lymphocytic infiltrates, and is not associated with the ulceration status of the primary tumor. 31501955 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE We here review the immunobiology of 2 particularly promising TNFRSF target receptors, CD27 and OX40, and their respective ligands, CD70 and OX40L, focusing on their role within a tumor setting. 29118006 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 AlteredExpression group BEFREE This suggests that interaction between OX40 on T cells and OX40-ligand on B cells may be important in modulating anti-tumor immune response. 24293009 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 AlteredExpression group BEFREE Fc-OX40L had single-agent activity in transplanted and spontaneous glioma models, and the pattern of inflammatory gene expression in the tumor predicted the degree of therapeutic response. 22781551 2012
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 Biomarker group BEFREE Pathways involving the costimulatory molecule OX40 and OX40 ligand (OX40L) enhance tumor rejection. 17975660 2007
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.090 AlteredExpression group BEFREE These results indicate that retroviral transduction of leukaemia-DCs with OX40L augments their antigen presenting cell activity and thus renders them more suitable for tumour vaccines or ex vivo stimulation of leukaemia-specific T cells. 14984494 2004